Key result
Higher baseline D-dimer is linked to ~171% greater VTE risk in advanced NSCLC.
Why the study?
To evaluate the incidence, timing, risk factors, and prognostic impact of venous thromboembolism in patients with advanced non-small cell lung cancer receiving systemic therapy.
Cohort (n=164)
No
Hazard Ratio: 2.714 (95% CI 1.97–3.741)
p-value: p=<0.001
In patients with advanced NSCLC receiving systemic therapy, VTE is a common early complication associated with elevated baseline D-dimer and significantly worse overall survival.
Supports vigilant VTE monitoring in advanced NSCLC; leaves open optimal prophylaxis strategies.
To evaluate the incidence, timing, risk factors, and prognostic impact of venous thromboembolism (VTE) in patients with advanced non-small cell lung cancer (NSCLC) receiving systemic therapy. This single-center retrospective cohort study included 164 consecutive patients with pathologically confirmed stage IIIB-IV NSCLC who initiated systemic therapy between January 2021 and December 2025. VTE events were identified during follow-up and objectively confirmed by imaging. The cumulative incidence of VTE was estimated using a competing-risk approach, with death before VTE treated as a competing event. Risk factors for incident VTE were evaluated using cause-specific Cox regression. The prognostic impact of VTE was assessed using time-dependent Cox regression. During follow-up, 29 patients developed VTE, corresponding to a crude proportion of 17.68%. The median time to first VTE was 104 days, and 24 of 29 events (82.76%) occurred within 6 months. When death before VTE was treated as a competing event, the cumulative incidence of VTE was 8.00% at 3 months, 15.04% at 6 months, and 17.97% at 12 months. In multivariable cause-specific Cox analysis, higher baseline D-dimer was independently associated with incident VTE (HR 2.714, 95% CI 1.970–3.741, P < 0.001). In a sensitivity model, anti-angiogenic therapy was associated with higher VTE risk (HR 2.810, 95% CI 1.320–5.984, P = 0.007). In time-dependent Cox analysis, VTE was independently associated with worse OS (HR 4.464, 95% CI 2.162–9.216, P < 0.001), but not PFS (HR 1.622, 95% CI 0.811–3.245, P = 0.172). VTE was a relatively common and early complication in patients with advanced NSCLC receiving systemic therapy. Baseline D-dimer was the most consistent factor associated with incident VTE, and VTE was independently associated with worse OS when analyzed as a time-dependent event. These findings support early risk assessment and vigilant clinical surveillance for thrombosis in advanced NSCLC.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) conducted a cohort in Advanced non-small cell lung cancer (NSCLC) (n=164). Higher baseline D-dimer vs. Lower baseline D-dimer was evaluated on Incident venous thromboembolism (VTE) (HR 2.714, 95% CI 1.970-3.741, p=<0.001). Higher baseline D-dimer was independently associated with an increased risk of incident venous thromboembolism (HR 2.714) in patients with advanced non-small cell lung cancer receiving systemic therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: